Bioline Rx EBIT

The latest EBIT for BLRX is $-460K as of March 2026. That compares with $-8.5M in the prior-year period — up 94.6% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Bioline Rx's historical trend and sector peers before judging valuation or financial health.

Over the past year, BLRX's EBIT moved from $-8.5M to $-460K — a 94.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bioline Rx's operating scale or balance-sheet position.

Against Healthcare companies, BLRX currently prints $-460K for EBIT, while the sector average sits near $22B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Bioline Rx's growth, margins, and balance sheet.

A EBIT figure of $-460K for BLRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting BLRX's EBIT ($-460K), review year-over-year change from $-8.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.